Program
Anti-PTK7 Antibody-drug Conjugate SKB518
Also written as “SKB518 for injection” and “SKB518”.
Its studies are mostly in Lung Neoplasms, led by Sichuan Kelun Pharmaceutical.
Drug pageAnti-PTK7 Antibody-drug Conjugate SKB518: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 2, since Jun 5, 20253 company-led studies, 3 open or runningNext primary completion: Feb 20, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 33 open or running | phase 2since Jun 5, 2025 | May 20, 2024 | Feb 20, 2027phase 2 · NCT07019675 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2024First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06428331 · 150 planned · China
- Jun 5, 2025Phase 2 study in Lung NeoplasmsNCT07019675 · 192 planned · China
- Feb 27, 2026Phase 2 study in Advanced Gynecological MalignanciesNCT07448922 · 280 planned · China
Ahead
- Feb 20, 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07019675
- Dec 31, 2027Primary completion: phase 2 study in Advanced Gynecological MalignanciesNCT07448922
TargetBeta
PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule
Other programs on PTK7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301rule | day-one-biopharmaceuticals-inc | phase 1 | 1 |
| Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408rule | Eli Lilly | phase 1 | 1 |
| Anti-PTK7 Antibody-drug Conjugate HWK-007rule | whitehawk-therapeutics-inc | phase 1 | 1 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07448922Advanced Gynecological Malignancies · China | 2 | Recruiting | Dec 31, 2027 | 280 |
| NCT07019675Lung Neoplasms · China | 2 | Recruiting | Feb 20, 2027 | 192 |
| NCT06428331Advanced Solid Tumors · China | 1 | Recruiting | Jun 30, 2026 | 150 |
How it is read
Names in the registry
- “SKB518 for injection”, 3 entries
- “SKB518”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.